PGAM
VRTX icon

Princeton Global Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Princeton Global Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.57M Sell
13,233
-30
-0.2% -$13.3K 0.94% 29
2026
Q1 		$5.92M Buy
13,263
+104
+0.8% +$48.5K 0.97% 27
2025
Q4 		$5.97M Sell
13,159
-200
-1% -$86.2K 0.97% 27
2025
Q3 		$5.23M Sell
13,359
-1,666
-11% -$696K 0.87% 29
2025
Q2 		$6.69M Sell
15,025
-186
-1% -$85.7K 1.21% 23
2025
Q1 		$7.37M Buy
15,211
+79
+0.5% +$36.8K 1.46% 19
2024
Q4 		$6.09M Sell
15,132
-74
-0.5% -$34.3K 1.14% 25
2024
Q3 		$7.07M Buy
15,206
+122
+0.8% +$58.6K 1.38% 18
2024
Q2 		$7.07M Buy
15,084
+880
+6% +$382K 1.56% 16
2024
Q1 		$5.94M Sell
14,204
-846
-6% -$358K 1.41% 18
2023
Q4 		$6.12M Buy
15,050
+255
+2% +$94.2K 1.54% 16
2023
Q3 		$5.14M Buy
14,795
+688
+5% +$241K 1.46% 16
2023
Q2 		$4.96M Sell
14,107
-1,261
-8% -$425K 1.45% 15
2023
Q1 		$4.84M Buy
15,368
+400
+3% +$120K 1.39% 17
2022
Q4 		$4.32M Sell
14,968
-55
-0.4% -$16.8K 1.4% 16
2022
Q3 		$4.35M Buy
15,023
+40
+0.3% +$11.5K 1.52% 15
2022
Q2 		$4.22M Sell
14,983
-219
-1% -$58.6K 1.36% 17
2022
Q1 		$3.97M Sell
15,202
-580
-4% -$138K 1.1% 23
2021
Q4 		$3.47M Sell
15,782
-1,058
-6% -$206K 0.97% 28
2021
Q3 		$3.06M Buy
16,840
+283
+2% +$55.3K 0.93% 30
2021
Q2 		$3.34M Sell
16,557
-652
-4% -$136K 1.02% 27
2021
Q1 		$3.7M Buy
17,209
+4
+0% +$879 1.2% 19
2020
Q4 		$4.07M Sell
17,205
-28
-0.2% -$6.42K 1.42% 17
2020
Q3 		$4.69M Buy
17,233
+258
+2% +$71.2K 1.89% 9
2020
Q2 		$4.93M Buy
16,975
+255
+2% +$69.1K 1.54% 12
2020
Q1 		$3.98M Buy
16,720
+2,175
+15% +$499K 1.76% 11
2019
Q4 		$3.18K Buy
14,545
+1,150
+9% +$233K 1.29% 18
2019
Q3 		$2.25M Buy
13,395
+446
+3% +$78.9K 1.28% 21
2019
Q2 		$2.38M Buy
12,949
+318
+3% +$55.6K 1.43% 17
2019
Q1 		$2.32M Sell
12,631
-7,180
-36% -$1.33M 1.59% 14
2018
Q4 		$3.28M Buy
+19,811
New +$3.43M 2.9% 4

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Princeton Global Asset Management's VRTX Position: Q2 2026 in Review

Princeton Global Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.23% in Q2 2026, selling an estimated $13.3K and leaving 13,233 shares worth $6.57M. The position accounts for 0.94% of the portfolio, ranked #29.

Princeton Global Asset Management first reported a position in VRTX in Q4 2018 and has held it in 31 quarters since. The position peaked at $7.37M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Princeton Global Asset Management held 13,233 shares of Vertex Pharmaceuticals worth $6.57M as of Q2 2026.
  • Princeton Global Asset Management sold 30 Vertex Pharmaceuticals shares in Q2 2026, an estimated $13.3K.
  • Vertex Pharmaceuticals made up 0.94% of Princeton Global Asset Management's portfolio in Q2 2026, its #29 holding.
  • Princeton Global Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
  • Princeton Global Asset Management's Vertex Pharmaceuticals position peaked at $7.37M in Q1 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Princeton Global Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.